Evidence map›Paper›PMID 34626407›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Isolation and Purification of Versican and Analysis of Versican Proteolysis.

Simon J Foulcer, Anthony J Day, Suneel S Apte

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. V3: an enigmatic isoform of the proteoglycan versican.American journal of physiology. Cell physiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Simon J FoulcerDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Anthony J DayWellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, UK.
Suneel S ApteDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. aptes@ccf.org.

Funding

VERSICAN PROTEOLYSIS AND REGULATION OF VASCULAR SMOOTH MUSCLEP01HL107147 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HASCALL, VINCENT CHARLES · 2011 to 2017
$16.1M
Endothelial protease activity, organogenesis and birth defectsR03HD069747 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI APTE, SUNEEL S · 2011 to 2012
$157k
Medical Research Council G0800127NHLBI NIH HHS P01 HL107147NICHD NIH HHS R03 HD069747
6 · The paper itself

Abstract

Versican is a widely distributed chondroitin sulfate proteoglycan that forms large complexes with the glycosaminoglycan hyaluronan (HA). As a consequence of HA binding to its receptor CD44 and interactions of the versican C-terminal globular (G3) domain with a variety of extracellular matrix proteins, versican is a key component of well-defined networks in pericellular matrix and extracellular matrix. Versican is crucial for several developmental processes in the embryo ranging from cardiac development to digit separation, and there is an increasing interest in its roles in cancer and inflammation. Versican proteolysis by ADAMTS proteases is highly regulated, occurs at specific peptide bonds, and is relevant to several physiological and disease mechanisms. In this chapter, methods are described for the isolation and detection of intact and cleaved versican in tissues using morphologic and biochemical techniques. These, together with the methodologies for purification and analysis of recombinant versican and an N-terminal versican fragment named versikine that are provided here, are likely to facilitate further progress on the biology of versican and its proteolysis.

Indexed as

ADAMTS ProteinsChondroitin Sulfate ProteoglycansExtracellular MatrixHyaluronic AcidLectins, C-TypeProteolysisVersicansADAMTS ProteinsChondroitin Sulfate ProteoglycansHyaluronic AcidLectins, C-TypeVersicansADAMTSA disintegrin-like and metalloprotease domain with thrombospondin type 1 motifAffinity chromatographyChondroitin sulfateExtracellular matrixGlycosaminoglycanHyaluronanVersican

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.